Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

University of Cologne

Status and phase: Completed; Phase 2

Conditions: Relapsed NLPHL

Treatments: Drug: Ofatumumab

Study type: Interventional

Funder types: Other

Identifiers

NCT01187303

Uni-Koeln-1432

Details and patient eligibility

About

The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).

Enrollment: 28 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• relapsed nodular lymphocyte predominant hodgkin lymphoma
• age 18 - 75
• review of diagnosis by experienced pathologist
• no major organ dysfunction

Exclusion criteria

• classical hodgkin lymphoma
• CD20 antibody treatment within the last 6 months prior enrollment
• chronic or current infectious disease requirering systemic antibiotics
• other past or current malignancy

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)